Domestic Pharma Growth in China to Outpace Exports
August 13, 2015.
Findings of the Pharma InsightsChina 2015 report, which follows the recent CPhI China 2015 event, reveal "an extremely positive outlook for growth in Chinese pharma, with the domestic market emerging as the driving force".
As the world’s second largest pharmaceutical economy, China will remain a rapidly expanding market, but unlike pharma manufacturing in the west, China’s growth is not dependent on exports and regulatory standards being met, the report explains.
On average, domestic respondents predict a near doubling in their sales over the next five years - almost 70% of companies surveyed said they are focusing chiefly on investing in APIs and generics. In addition, IMS Health research showed that growth is not uniform across the market and ‘emerging cities’ have the highest growth potential, which is where domestic manufacturers are now looking to target their business efforts.
For a free copy of the online Pharma Insights report, please visit:
www.cphi.com/europe/networking/cphi-pharma-insights
Is Artificial Intelligence a ‘Product’? Products Liability Implications for AI-Based Products
April 10th 2025As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not always fit to provide remedies for harm that can result from using novel product types.
